A 2-year prospective, multicenter, randomized controlled, and double-blind clinical trial is used to investigate the efficacy of a new design of ophthalmic lenses to slow the progression of myopia. 300 children aged from 6 to 13 years old will be recruited and randomly assigned to a study or control group. The study group will be composed of 150 children wearing MyoCare while the control group will be composed of 150 children wearing Clearview. The inclusion criteria will be myopia with a spherical equivalent between -0.75D and -5.00D, astigmatism < 1.50D, and anisometropia < 1.00D, as well as having a historical evolution of at least -0.50 The primary outcome is to compare the mean annual progression of the spherical equivalent between both groups. The secondary outcomes are axial length, choroidal thickness, phorias, and accommodative status of both groups.

Inclusion Criteria:

• Age 6-13 years
• Caucasian ethnicity
• Monocular/binocular decimal visual acuity with correction ≥ 1.00
• Spherical equivalent between -0.75D and -5.00D
• Astigmatism < 1.50D
• Anisometropia < 1.00D
• Evolution of at least -0.50D in one year

Exclusion Criteria:

• Presence of ocular pathology or a history of ocular and systemic abnormalities
• Strabismus or binocular vision problems
• History of eye surgery
• Having previously used some method to control myopia.
• Having contraindications for the application of drugs for cycloplegia/corneal anesthesia